Molecular and histological profiling classifies BC into three major subtypes: those expressing the hormone receptors of BC (estrogen receptor (ER) or progesterone receptor (PR)), those expressing human epidermal growth factor receptor 2 (HER2) of BC, and triple-negative breast cancer (TNBC) (Barzaman et al., 2020). Here, PGR is linked to triple-negative breast carcinoma.